How KLOW Became the Default Wellness Stack

A Conference Slide, Late 2023

I spent a weekend trying to pin down the exact moment KLOW stopped being a niche compounded vial and started being a default. The exact moment is impossible to pin down. What we have instead is a composite. By various accounts from practitioners active in the space, somewhere in the second half of 2023, at one of the larger functional medicine conferences (A4M's fall meeting in Las Vegas is the one most often named, though I cannot independently verify which session), a presenter clicked through a slide deck on regenerative protocols and mentioned KLOW by name. The room took notes. By the next big practitioner gathering, multiple speakers were referencing it. By spring 2024, you could not walk through the exhibitor hall at A4M without seeing it on a banner. That is the conference version of the story. The Instagram version is shorter. Sometime in the first quarter of 2024, a med-spa account in Florida (or Texas, or Southern California, accounts vary) posted a "now offering KLOW" announcement with the typical clinical photography. The post got a few hundred saves. Within a few months, similar posts appeared from dozens of competing clinics. Within a year, the announcement was so ubiquitous that the format had more or less hardened: same lighting, same vial-in-hand framing, same caption structure listing the four components. The telehealth version is the version with the most paper trail. Provider portals at major compounding pharmacies began carrying pre-formulated KLOW blends sometime in 2024. Telehealth platforms followed within weeks. By Q3 2024, KLOW was a standard line item across the larger consumer-facing peptide telehealth services. All three of these versions are, more or less, the same story. The eighteen-month window from late 2022 to mid-2024 was when KLOW went from "thing one or two compounding pharmacies were experimenting with" to "thing every wellness clinic was offering." How that happened is the actual subject of this piece.

The World Before KLOW

To understand KLOW's adoption arc, you have to understand what the wellness peptide market looked like in late 2021 through mid-2022. It was small. Trade press estimates from that period put the U.S. wellness peptide market somewhere in the range of two to four hundred million dollars annually, fragmented across a few thousand med-spas, a smaller number of functional medicine clinics, and a growing but still-immature telehealth segment. Compounding pharmacies were the supply backbone. Med-spas were the retail front. The dominant products in any given clinic's brochure were predictable: GLOW for skin and aesthetic positioning, CJC-1295 paired with ipamorelin for the growth-hormone-axis crowd, sermorelin for clinics that wanted something with a longer regulatory track record. Most practitioners were running protocols that had not changed materially in five years. Telehealth was scaling fast. The post-COVID acceleration in tele-prescribing had reshaped how mid-market wellness products reached consumers. By mid-2022, platforms that had been general telehealth services in 2020 were carving out peptide-specific verticals. The infrastructure was being built. The product menus were waiting to be filled. If you've ever been to an A4M conference, you know the rhythm. The same speakers cycle through the same protocols. Dosing tables get reused for two or three years before someone updates them. Innovation in the space tends to come from one of two places: a researcher with a single new compound, or a compounding pharmacy that figures out how to combine existing compounds in a slightly new way. KLOW came from the second category. There was something else happening in 2022 that mattered. The original GLOW stack (a three-peptide combination of GHK-Cu, BPC-157, and TB-500) had reached a kind of saturation. Practitioners liked it. Clients liked it. But it had a known gap. It did not address gut and inflammation pathways particularly well. Several practitioners, by various accounts, were already adding KPV separately to their GLOW protocols by late 2022. The next obvious step was for someone to package it as a single vial.

Late 2022: The First Vials

I have not been able to determine which compounding pharmacy first formulated and shipped KLOW under that exact name. The honest answer is that several of them probably did, more or less independently, between late 2022 and early 2023. Empower Pharmacy and Olympia Pharmacy were the two most-named compounders in trade conversations from that period, though both have since been swept up in the FDA's 2023 Category 2 changes that altered everyone's compounding posture. Smaller regional players were almost certainly doing it too. The naming is part of why this took off when it did. KLOW, as a brand, is a near-perfect upgrade name. It rhymes with GLOW. It looks like GLOW with a single letter swapped. It implies that you are getting GLOW plus something extra, which, depending on which version of the stack, you are, in practice. Practitioners did not have to learn a new product story. They had to learn an upgrade story. The cognitive load of selling KLOW to an existing GLOW patient was approximately zero. The earliest documented mentions on biohacker forums (Reddit's r/Peptides and the longer-running peptide threads at MESO-Rx, mostly) appear in late 2022 and early 2023. The framing was already mature. Posts described KLOW not as a novel formulation but as "GLOW with KPV added," which is how compounding pharmacies were describing it to provider clients. The forums had a head start of maybe six months over the conferences. Actually, that is not quite right. Let me rephrase. The forums had a head start over the large conferences. Smaller practitioner gatherings (regional A4M chapter meetings, IFM continuing education modules, anti-aging-medicine practitioner masterminds) had been discussing four-peptide regenerative stacks for some time. KLOW was less the invention of a new idea than the standardization of an existing one.

2023: The Adoption Channels

By spring 2023, KLOW was moving through four adoption channels in parallel. Tracking them separately is the easiest way to understand why the adoption curve was so steep. Functional medicine conferences. A4M's spring 2023 meeting in Orlando, by various practitioner accounts, was the first major conference where KLOW appeared explicitly in slide decks. The presentations were largely informal: case-series anecdotes from practitioners who had been running the protocol on their own clients for six to twelve months, plus the obligatory mechanism-summary slide that practitioners later cribbed verbatim into their own marketing materials. IFM modules picked it up later. ACAM and the smaller regional circuits followed. Conference adoption is a lagging indicator, not a leading one, but it matters because it is what gives mid-tier practitioners the cover to start prescribing. Functional medicine podcasts. The podcast layer is harder to track because most of the podcasts that drove peptide-curiosity in this period (Bulletproof Radio, the Ben Greenfield catalog, Peter Attia's universe, Mark-Hyman-adjacent shows) did not directly promote KLOW by name. They created the cultural environment in which someone hearing "four-peptide regenerative stack" would already feel a pull. The actual product-naming work happened lower in the stack: practitioner-run podcasts with smaller audiences, integrative medicine practitioner Substacks, the long tail of YouTube content from practitioners who had moved their practices online. Instagram and TikTok med-spa accounts. This is where the visual language of KLOW got cemented. The "now offering" post, the components-listed-out caption, the gloved-hand-holding-vial photography, the before-and-after testimonial reels. By late 2023, you could scroll for an hour through aesthetic-medicine Instagram and not go more than a few accounts without seeing it. TikTok lagged Instagram by maybe two quarters but caught up by mid-2024. Compounding pharmacy provider portals. This is the channel that actually moved volume. When a major compounding pharmacy adds a pre-blended SKU to its provider portal, several thousand prescribing practitioners can switch their protocols overnight. The pharmacies kept the marketing relatively quiet. The provider-side adoption was loud. By mid-2023, KLOW was a stocked SKU at most of the larger 503A pharmacies serving the wellness space, and by late 2023 many of the regional players were carrying it too. The four channels reinforced each other. Practitioners saw KLOW at a conference, mentioned it to a patient who had already seen it on Instagram, prescribed it through a compounding pharmacy that had added it to the portal, and then posted a "now offering" announcement that fed the next practitioner's discovery. The cycle compounded faster than any single channel could have.

September 2023: The Disruption

In September 2023, the FDA placed both BPC-157 and TB-500 on Category 2 of its 503A bulks list. The agency cited "significant safety risks." The legal effect was immediate: compounding pharmacies could no longer prepare either compound for human use. Two of KLOW's four components were now off-limits. The other two (GHK-Cu in its non-injectable form, and KPV) sat in different regulatory positions, but the four-peptide formulation as a whole could no longer legally be compounded. The supply chain shifted within weeks. Some compounding pharmacies stopped offering KLOW entirely. Others moved to "research only" labeling and kept selling. A third group began sourcing finished product from overseas suppliers and distributing under disclaimer-protected research-chemical structures, the same channel that was already absorbing GLOW, the Wolverine Stack, and most of the compounded peptide market that the FDA had just disrupted. Adoption slowed. It did not stop. Trade press coverage from late 2023 and early 2024 documents the same pattern across the broader peptide market: compounding-pharmacy volume contracted, research-chemical-channel volume expanded, telehealth platforms restructured but kept selling. KLOW was a beneficiary of the ambiguity rather than a casualty of the regulation. Practitioners who had been on the fence about prescribing it before September 2023 mostly stayed on whatever side of the fence they had been on. The market fragmented. It also kept growing. The interesting question is why the regulatory disruption did not slow adoption more than it did. Part of the answer is that practitioners read the regulation as a procedural action, not a substantive one. Part of it is that the wellness industry had a recent template for how to route around exactly this kind of restriction (the GLP-1 compounding battle was happening at the same time). And part of it is that consumer demand had already crossed a threshold. Once an Instagram-driven product becomes a brand, regulatory friction redirects the supply chain rather than killing the product.

Why KLOW Won Over Competing Stacks

There were other four-peptide stacks. Several compounding pharmacies floated alternatives in 2023 and 2024. None of them stuck the way KLOW did. The naming was the easiest factor to identify. GLOW and KLOW pair phonetically and visually in a way that other naming attempts simply did not. A patient who had been on GLOW for a year could move to KLOW without feeling like they were starting a new protocol. The marketing was already half-built. The KPV addition addressed a specific clinical pain point. The original three-peptide GLOW stack had a known gap on gut and inflammation. Practitioners had been adding KPV separately, which created dosing complications and patient adherence issues. A single-vial preparation that bundled KPV in solved a problem practitioners were already solving with worse tools. The pricing differential mattered less than you might expect. The retail spread between a GLOW cycle (which by 2023 was running at around $250 to $300 in most clinics) and a KLOW cycle (typically $300 to $400) was small enough that practitioners could position the upgrade without resistance. For a clinic running peptide protocols on regular subscription clients, moving the average cycle price up by fifty dollars while adding what the marketing copy could honestly call "broader coverage" was an easy sell. There is one more factor that I think matters more than it gets credit for. Compounding pharmacies preferred carrying a slight variant of an existing product over an entirely new SKU. The supply-chain economics of stocking a four-peptide blend that uses three of the same components as your existing three-peptide blend are dramatically better than the economics of stocking a completely novel formulation. KLOW was not just easy to sell to patients. It was easy to sell to pharmacies.

October 2024: A Cautionary Parallel

On October 29, 2024, the FDA's Pharmacy Compounding Advisory Committee voted against adding ipamorelin to the 503A bulks list. On December 4, the same committee voted against CJC-1295. The combined effect ended the procedural ambiguity that had briefly reopened compounding for the GH-axis stack that had been the wellness industry's other anchor product. We have written elsewhere about the parallel CJC-1295 case, which has its own twenty-year history; the relevant point here is that the PCAC vote shifted practitioner psychology more than the underlying regulation did. The message practitioners absorbed was straightforward. The FDA had not just restricted compounding once and walked away. It was actively reviewing peptides one by one, and the reviews were going against the wellness industry. CJC-1295 and ipamorelin had been legally compoundable for decades before the 2023 reset. They were not going to be again, at least not without significantly more clinical evidence than anyone had funded. For KLOW itself, the PCAC vote was a parallel cautionary tale rather than a direct hit. None of KLOW's four components had been through a PCAC vote in 2024. (BPC-157 and TB-500 had been placed on Category 2 procedurally; they had not been formally reviewed and rejected.) But the broader regulatory direction was clear, and a meaningful number of practitioners pulled back during the November-to-December 2024 window. Others doubled down on the research-chemical channel. The market did not consolidate. It diversified its risk. What happened next isn't entirely clear, even now. The 2024 PCAC pattern suggested that any peptide brought to a formal vote would lose. But no peptide had been brought to a formal vote since.

February to April 2026: The Reset

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. went on the Joe Rogan Experience and announced his intent to move most of the Category 2 peptides back to Category 1, where compounding would once again be permitted. He framed the original FDA decision as an overreach. In April 2026, twelve peptides came off Category 2 because their original nominators withdrew their nominations. BPC-157 and TB-500 were among them. The procedural mechanism for blocking compounded preparation of two of KLOW's four components disappeared, at least for now. The Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24, 2026, to discuss whether any of these peptides should be formally added to the 503A bulks list. For KLOW, the 2026 reset is less of a clean win than it might look. BPC-157 and TB-500 sit in the more favorable procedural position because they never received an explicit PCAC vote against them. KPV's path is more complicated. GHK-Cu's status is bifurcated by route of administration in ways that affect injectable formulations differently from topical ones. The four components are not moving through the regulatory system as a single block. They are moving through it as four separate negotiations, and KLOW as a product depends on all four of them landing in compatible places. Compounding pharmacies have begun quietly re-stocking the components. Telehealth platforms have begun scheduling reactivation campaigns timed to whatever the July advisory committee meeting produces. Whether the reset translates into a true restoration of the pre-2023 supply chain depends on procedural outcomes that haven't been written yet.

Where This Goes Next

Three things to watch over the next year and a half. Whether telehealth platforms expand or contract. The platforms that scaled their KLOW menus through 2024 and 2025 are now sitting on customer lists. If the 2026 reset holds and the PCAC outcomes are partially favorable, expect aggressive expansion of compounded KLOW offerings during 2027. If the PCAC outcomes go the way the 2024 votes did, expect quiet rollback to research-chemical-channel sourcing. Whether competing four-peptide stacks emerge. KLOW's market position is durable but not unassailable. There is room for a five-peptide stack that adds something like Tβ4-Frag or an analog with stronger published evidence. A handful of compounding pharmacies have floated trial balloons in this direction. None of them have stuck yet. Whether one will in the next eighteen months is the more interesting product-strategy question. Whether enforcement against research-chemical sellers tightens. Kennedy's stated position is that he wants to "shift demand away from the black market," which the wellness industry has read as meaning expanded compounding access. The unintended (or intended) implication is that enforcement against research-only vendors might tighten. The historical FDA pattern is that enforcement resources are limited and that aggressive action against research-chemical labels is rare. The current administration has signaled different priorities. Whether action follows the rhetoric is the open question.

Bottom Line

KLOW's story is a case study in how wellness products spread through informal channels faster than regulators can track them. The eighteen-month sprint from late 2022 to mid-2024 was not driven by science, marketing budgets, or regulatory legitimacy. It was driven by the alignment of four parallel adoption channels (conferences, podcasts, Instagram, compounding-pharmacy provider portals) that reinforced each other faster than any single one of them could have moved alone. The 2023 regulatory disruption did not kill KLOW. It redirected the supply chain. The 2024 PCAC parallel did not kill KLOW. It changed practitioner psychology at the margins. The 2026 reset has not yet produced a clear answer, and it might not for another year. The deeper question is whether KLOW's adoption pattern is a one-off or a template. If it is a template, the next four-peptide stack will move through the same channels in the same sequence and arrive at the same default position within a similar timeframe. If it is a one-off, the conditions that produced it (post-COVID telehealth scale, the GLOW-to-KLOW upgrade narrative, the specific regulatory window between September 2023 and now) will not repeat. I genuinely do not know which it is. Neither, by all available evidence, do the people running the compounding pharmacies.